Myriad Genetics, Inc. (MYGN)
After hours:
| Previous Close | 22.37 |
| Open | 22.34 |
| Bid | 17.00 x 1400 |
| Ask | 22.05 x 1100 |
| Day's Range | 21.90 - 22.58 |
| 52 Week Range | 18.98 - 36.95 |
| Volume | |
| Avg. Volume | 563,350 |
| Market Cap | 1.768B |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.35 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.33 |
- Zacks
Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
- Zacks
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectivelyEnded the quarter with $339.2 million in cash, cash equivalents and investmentsNew partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selectio
